Cargando…
Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis
Patients with hematological malignancy and COVID-19 display a high mortality rate. In such patients, immunosuppression due to underlying disease and previous specific treatments impair humoral response, limiting viral clearance. Thus, COVID-19 convalescent plasma (CCP) therapy appears as a promising...
Autores principales: | Hueso, Thomas, Godron, Anne-Sophie, Lanoy, Emilie, Pacanowski, Jérôme, Levi, Laura I., Gras, Emmanuelle, Surgers, Laure, Guemriche, Amina, Meynard, Jean-Luc, Pirenne, France, Idri, Salim, Tiberghien, Pierre, Morel, Pascal, Besson, Caroline, Duléry, Rémy, Lamure, Sylvain, Hermine, Olivier, Gagneux-Brunon, Amandine, Freymond, Nathalie, Grabar, Sophie, Lacombe, Karine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805670/ https://www.ncbi.nlm.nih.gov/pubmed/35105946 http://dx.doi.org/10.1038/s41375-022-01511-6 |
Ejemplares similares
-
A look-back at convalescent plasma to treat COVID-19
por: Garraud, Olivier, et al.
Publicado: (2021) -
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
por: Hueso, Thomas, et al.
Publicado: (2020) -
L-66 Le plasma convalescent COVID-19 pour le traitement de la COVID-19
por: Tiberghien, Pierre, et al.
Publicado: (2022) -
Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
por: London, Jonathan, et al.
Publicado: (2020) -
Convalescent plasma to treat COVID-19: Following the Argentinian lead
por: Tiberghien, Pierre, et al.
Publicado: (2021)